Beovu (Brolucizumab)
Brand Names: Beovu
Methodology & AI Transparency ⓘ
Beovu (Brolucizumab) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Beovu is a prescription brand-name fda prescription therapeutic agent product delivering active pharmaceutical ingredient Brolucizumab, registered by Novartis Pharmaceuticals Corporation under NDC 0078-0827.
- 2 Real-world patient consensus: Beovu links directly to generic Brolucizumab under FDA SPL 2026-07-01 (NDC 0078-0827).
- 3 Typical cash cost range: Dispensing cost comparison spans $41.62 mail/discount cash up to $110.29 uninsured retail (federal NADAC $0.4600).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Beovu (Brolucizumab): nausea (7.7%), headache (6.7%), dizziness (6%).
Ask our AI Specialists anything about Beovu (Brolucizumab)
Beovu (Brolucizumab) Mechanism, CYP450 Pathways & DailyMed Monograph
Beovu is a prescription brand-name fda prescription therapeutic agent product delivering active pharmaceutical ingredient Brolucizumab, registered by Novartis Pharmaceuticals Corporation under NDC 0078-0827. Updated in FDA DailyMed SPL on 2026-07-01, this branded presentation (6 mg/.05mL Injection, Solution; 6 mg) supports As a federal NDC-monographed fda prescription therapeutic agent (0078-0827, manufactured/labeled by Novartis.
Pharmacologically, Beovu derives its clinical activity from Brolucizumab, a fda prescription therapeutic agent molecule with class-characteristic hepatorenal disposition. Branded finished-dosage manufacturing (6 mg/.05mL Injection, Solution; 6 mg; registered by Novartis Pharmaceuticals Corporation) governs excipient dissolution and release kinetics while maintaining bioequivalence benchmarks relative to reference Brolucizumab (CMS NADAC $0.4600/unit vs. $110.29 retail).
Pharmacokinetic profiling of Beovu (Brolucizumab) demonstrates an elimination half-life of Terminal t½ estimated at 7–14 hrs depending on renal/hepatic reserve (Beovu (Brolucizumab)) with Complete (~100%) parenteral systemic delivery for Beovu (Brolucizumab) (6 mg/.05mL Injection, Solution) systemic bioavailability; clearance proceeds via mixed metabolic conjugation and unchanged urinary excretion across beovu (brolucizumab) regimens, reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after beovu (brolucizumab) administration.
Titration schedules for Beovu (Brolucizumab) (6 mg/.05mL Injection, Solution → 6 mg → 05mL) require excluding prior anaphylaxis, angioedema, or severe hypersensitivity to brolucizumab or beovu (brolucizumab) excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 beovu (brolucizumab) spl; real-world patient logs highlight nausea (7.7% of reports), headache (6.7% of reports), dizziness (6% of reports) alongside a 75.00% Worth-It consensus.
Avoid overlapping fda prescription therapeutic agent prescriptions alongside Beovu (Brolucizumab) to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Beovu (Brolucizumab) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Brolucizumab or Beovu (Brolucizumab) excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 Beovu (Brolucizumab) SPL
Logged Side-Effect Incidence (20 Reports)
Beovu (Brolucizumab) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Beovu (Brolucizumab))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE: What a 1,752-Participant Study Found More stable CST was associated with better visual outcomes at the end of treatment suggesting that CST variability may provide a more reliable prognostic marker of visual outcomes than the presence of fluid alone, with the... Retina (Philadelphia, Pa.) • 2022-03-01 • Phase III Randomized Trial | N = 1,752 | 90/100 | PMID 34923515 ↗ |
| New Insights on KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients: What a 566-Participant Study Found Results show the long-term efficacy and durability of brolucizumab in improving visual and anatomical outcomes in DME; the overall safety profile of brolucizumab remained unchanged through year 2. American journal of ophthalmology • 2024-04-15 • Phase III Randomized Trial | N = 566 | 87/100 | PMID 37460036 ↗ |
| Can This Approach Help? Inside the Latest Research on MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Visual acuity outcomes in previously treated participants with nAMD and persistent retinal fluid receiving brolucizumab 6 mg dosed every 4 weeks were noninferior to aflibercept 2 mg dosed every 4 weeks, with superior anatomic... Ophthalmology • 2022-09-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 35537533 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Findings of this analysis highlight the need for continued vigilance and monitoring for any signs of IOI-related events in patients receiving brolucizumab. Ophthalmology. Retina • 2022-02-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33971353 ↗ |
Beovu (Brolucizumab) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.4600/unit (~$13.80/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $110.29 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $41.62 / mo | View logs ↓ |
Beovu (Brolucizumab) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Beovu (Brolucizumab) RxNorm Concept ID | RXN-B00780827 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.4600 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $110.29 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $41.62 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 75.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Beovu (Brolucizumab) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Beovu (Brolucizumab) (fda prescription therapeutic agent) monograph synthesizing RxNorm RXN-B00780827, openFDA FAERS signals, and $41.62–$110.29 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Beovu (Brolucizumab) community threads and patient logs by age, biological sex, dosage, and treatment duration.